{"id":"chop-r","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Thrombocytopenia"},{"rate":"10-20%","effect":"Infection"},{"rate":"10-20%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL89731","moleculeType":"Small molecule","molecularWeight":"159.14"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The CHOP-R regimen is used to treat various types of non-Hodgkin lymphoma. Rituximab is a monoclonal antibody that targets the CD20 protein on the surface of B cells, while the CHOP regimen works by killing cancer cells through different mechanisms. The combination of these drugs is thought to be more effective than using CHOP alone.","oneSentence":"CHOP-R is a chemotherapy regimen that combines rituximab with a modified version of the CHOP regimen, which includes cyclophosphamide, doxorubicin, vincristine, and prednisone.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:08:01.573Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-Hodgkin lymphoma"}]},"trialDetails":[{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":"Primary Mediastinal Large B-Cell Lymphoma","enrollment":244},{"nctId":"NCT07494565","phase":"PHASE2","title":"Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-05","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL), CD5 Positive","enrollment":60},{"nctId":"NCT03269669","phase":"PHASE2","title":"Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-23","conditions":"Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma","enrollment":73},{"nctId":"NCT03984448","phase":"PHASE2, PHASE3","title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-22","conditions":"Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma","enrollment":363},{"nctId":"NCT01856192","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-08-27","conditions":"Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma","enrollment":349},{"nctId":"NCT06717347","phase":"PHASE3","title":"A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-01-27","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":1046},{"nctId":"NCT07444710","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-20","conditions":"Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma, Ann Arbor Stage IV Mantle Cell Lymphoma","enrollment":16},{"nctId":"NCT07493148","phase":"PHASE2","title":"Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL","status":"RECRUITING","sponsor":"Ou Bai, MD/PHD","startDate":"2026-04-30","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":50},{"nctId":"NCT07493109","phase":"PHASE3","title":"Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP","status":"RECRUITING","sponsor":"Ou Bai, MD/PHD","startDate":"2026-05-30","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":200},{"nctId":"NCT05888493","phase":"PHASE3","title":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-02","conditions":"Follicular Lymphoma (FL)","enrollment":109},{"nctId":"NCT07215585","phase":"PHASE3","title":"AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-11","conditions":"Large B-cell Lymphoma","enrollment":420},{"nctId":"NCT06549595","phase":"PHASE3","title":"A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-08-07","conditions":"Untreated Follicular Lymphoma","enrollment":1018},{"nctId":"NCT06313996","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma","status":"WITHDRAWN","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2024-03-29","conditions":"Relapsed or Refractory Follicular Lymphoma","enrollment":""},{"nctId":"NCT07476105","phase":"NA","title":"Geriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymphoma in First Line Treatment","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2026-05","conditions":"Diffuse Large B Cell Lymphoma, Follicular Lymphoma Grade 3B","enrollment":170},{"nctId":"NCT07029737","phase":"PHASE2","title":"A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-09-05","conditions":"Mantle-cell Lymphoma","enrollment":55},{"nctId":"NCT05800366","phase":"PHASE2","title":"A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Jennifer Crombie, MD","startDate":"2023-04-06","conditions":"Lymphoma, Lymphoma, Large B-Cell, Diffuse","enrollment":41},{"nctId":"NCT04623541","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-25","conditions":"Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome","enrollment":195},{"nctId":"NCT04663347","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-03","conditions":"Diffuse Large B-Cell Lymphoma, Follicular Lymphoma","enrollment":543},{"nctId":"NCT06191744","phase":"PHASE3","title":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2024-02-05","conditions":"Follicular Lymphoma (FL)","enrollment":1095},{"nctId":"NCT04542824","phase":"PHASE1, PHASE2","title":"Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-08-20","conditions":"Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma","enrollment":78},{"nctId":"NCT05605899","phase":"PHASE3","title":"Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2023-02-10","conditions":"High-risk Large B-cell Lymphoma (LBCL)","enrollment":300},{"nctId":"NCT07443514","phase":"NA","title":"Cognitive Impairment in Patients With Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Institute of Oncology Ljubljana","startDate":"2022-01-01","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":3},{"nctId":"NCT04002947","phase":"PHASE2","title":"Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-05","conditions":"Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma, DLBCL","enrollment":132},{"nctId":"NCT04980222","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-03-22","conditions":"Lymphoma","enrollment":46},{"nctId":"NCT06517511","phase":"PHASE2","title":"Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-08-01","conditions":"Diffuse Large B Cell Lymphoma","enrollment":42},{"nctId":"NCT06356129","phase":"PHASE3","title":"Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2024-06-19","conditions":"Large B-cell Lymphoma","enrollment":850},{"nctId":"NCT04214444","phase":"PHASE3","title":"Evaluation of Prime-boost Anti-pneumococcal Vaccination in Patients With Diffuse Large B Cell Lymphoma Treated With Rituximab","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2020-07-03","conditions":"Pneumococcal Infections, Lymphoma, Large B-Cell, Diffuse","enrollment":26},{"nctId":"NCT07398638","phase":"PHASE1, PHASE2","title":"Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-28","conditions":"Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":122},{"nctId":"NCT03758989","phase":"PHASE2","title":"A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma","status":"RECRUITING","sponsor":"University of Rochester","startDate":"2019-05-08","conditions":"DLBCL","enrollment":40},{"nctId":"NCT04850495","phase":"PHASE1","title":"Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma","status":"SUSPENDED","sponsor":"Yazeed Sawalha","startDate":"2021-11-16","conditions":"Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma","enrollment":38},{"nctId":"NCT03274492","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-11-16","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":1000},{"nctId":"NCT06097364","phase":"PHASE3","title":"A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-11-14","conditions":"Follicular Lymphoma (FL)","enrollment":733},{"nctId":"NCT06564038","phase":"PHASE1, PHASE2","title":"A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-01-30","conditions":"Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma","enrollment":276},{"nctId":"NCT06091865","phase":"PHASE3","title":"A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-12-13","conditions":"Diffuse Large B-cell Lymphoma (DLBCL)","enrollment":904},{"nctId":"NCT04884035","phase":"PHASE1","title":"Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma","status":"RECRUITING","sponsor":"Celgene","startDate":"2021-09-15","conditions":"Lymphoma, B-Cell","enrollment":174},{"nctId":"NCT05782374","phase":"","title":"Real World Data on Ibrutinib Use in PCNSL Rel/Ref","status":"ACTIVE_NOT_RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2022-08-10","conditions":"PCNSL","enrollment":36},{"nctId":"NCT04323956","phase":"PHASE1","title":"Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2020-06-15","conditions":"Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma","enrollment":50},{"nctId":"NCT06829771","phase":"PHASE1, PHASE2","title":"Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-23","conditions":"Diffuse Large B Cell Lymphoma","enrollment":90},{"nctId":"NCT03943901","phase":"PHASE2","title":"Split-Dose R-CHOP for Older Adults With DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2021-02-17","conditions":"Diffuse Large B Cell Lymphoma, DLBCL, Cancer","enrollment":27},{"nctId":"NCT07372365","phase":"PHASE2","title":"Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-10-24","conditions":"Marginal Zone Lymphoma (MZL)","enrollment":23},{"nctId":"NCT06846463","phase":"PHASE2","title":"Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+","status":"RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2025-05-27","conditions":"Diffuse Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma","enrollment":21},{"nctId":"NCT07348575","phase":"PHASE3","title":"A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma","status":"ENROLLING_BY_INVITATION","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2024-07-01","conditions":"Lymphoma, Large-Cell, Diffuse","enrollment":80},{"nctId":"NCT07335120","phase":"","title":"A Real-world Data and Sample Compendium of Frail and/or Multiply Treated Large B-cell Lymphoma","status":"RECRUITING","sponsor":"The Clatterbridge Cancer Centre NHS Foundation Trust","startDate":"2024-10-30","conditions":"DLBCL","enrollment":800},{"nctId":"NCT06425302","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2024-08-30","conditions":"Lymphoma, Follicular","enrollment":90},{"nctId":"NCT03463057","phase":"PHASE2","title":"The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2018-08-30","conditions":"NHL, DLBCL","enrollment":109},{"nctId":"NCT06220032","phase":"PHASE3","title":"Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma","status":"RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2024-08-15","conditions":"DLBCL - Diffuse Large B Cell Lymphoma","enrollment":324},{"nctId":"NCT06141772","phase":"NA","title":"Kinetics of Circulating Tumor DNA in Lymphoma Treated by Immuno-chemotherapy","status":"COMPLETED","sponsor":"Centre Henri Becquerel","startDate":"2023-12-21","conditions":"Diffuse Large B Cell Lymphoma","enrollment":24},{"nctId":"NCT04604067","phase":"PHASE2","title":"Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2021-06-25","conditions":"Diffuse Large B-cell Lymphoma","enrollment":260},{"nctId":"NCT03731234","phase":"PHASE2","title":"Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2019-07-02","conditions":"DLBCL","enrollment":75},{"nctId":"NCT04529772","phase":"PHASE3","title":"A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2020-10-08","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":611},{"nctId":"NCT04696692","phase":"NA","title":"Single-Cell Map of Immune and Lymphoma Cells in B-cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Institut Claudius Regaud","startDate":"2021-02-09","conditions":"Diffuse Large B-cell Lymphoma","enrollment":60},{"nctId":"NCT06006117","phase":"PHASE3","title":"Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2023-09-05","conditions":"Marginal Zone Lymphoma","enrollment":260},{"nctId":"NCT04661007","phase":"PHASE1, PHASE2","title":"To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Biosciences Japan GK","startDate":"2020-12-15","conditions":"Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma","enrollment":72},{"nctId":"NCT04594798","phase":"PHASE2","title":"A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Rochester","startDate":"2021-09-20","conditions":"DLBCL, Lymphoma, B-Cell","enrollment":39},{"nctId":"NCT07278856","phase":"PHASE1","title":"Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-04-27","conditions":"Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Follicular Helper T-Cell Lymphoma, Follicular-Type","enrollment":20},{"nctId":"NCT06186648","phase":"PHASE2","title":"Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome","status":"RECRUITING","sponsor":"French Innovative Leukemia Organisation","startDate":"2024-03-21","conditions":"Richter Syndrome","enrollment":40},{"nctId":"NCT06911502","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)","status":"RECRUITING","sponsor":"Celgene","startDate":"2025-07-28","conditions":"Follicular Lymphoma","enrollment":400},{"nctId":"NCT06520163","phase":"PHASE3","title":"Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2024-08-01","conditions":"Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization","enrollment":99},{"nctId":"NCT04214626","phase":"PHASE2","title":"R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Henan Cancer Hospital","startDate":"2020-01-05","conditions":"Diffuse Large B Cell Lymphoma","enrollment":60},{"nctId":"NCT02916316","phase":"","title":"Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2014-02-12","conditions":"Lymphoma, Large B-Cell, Diffuse Large B-Cell","enrollment":127},{"nctId":"NCT07220187","phase":"PHASE3","title":"Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial","status":"NOT_YET_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2026-05-02","conditions":"Richter Syndrome, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma","enrollment":102},{"nctId":"NCT05371093","phase":"PHASE3","title":"Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2022-09-22","conditions":"Relapsed/Refractory Follicular Lymphoma","enrollment":231},{"nctId":"NCT00690560","phase":"PHASE2","title":"Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Centre Antoine Lacassagne","startDate":"2007-05","conditions":"Lymphoma","enrollment":30},{"nctId":"NCT01650701","phase":"PHASE3","title":"A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2012-02","conditions":"Follicular Lymphoma","enrollment":1030},{"nctId":"NCT07181785","phase":"","title":"Molecular Characterization and Outcomes of Aggressive B-Cell Lymphomas.","status":"COMPLETED","sponsor":"Andrés José Maria Ferreri","startDate":"2022-07-12","conditions":"Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":555},{"nctId":"NCT04824092","phase":"PHASE3","title":"Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2021-05-11","conditions":"Diffuse Large B-cell Lymphoma","enrollment":899},{"nctId":"NCT05058404","phase":"PHASE3","title":"Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2021-12-01","conditions":"Follicular Lymphoma","enrollment":605},{"nctId":"NCT07059650","phase":"PHASE1, PHASE2","title":"DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)","status":"RECRUITING","sponsor":"Dizal Pharmaceuticals","startDate":"2025-08-19","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":150},{"nctId":"NCT00278408","phase":"PHASE3","title":"Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"German High-Grade Non-Hodgkin's Lymphoma Study Group","startDate":"2006-01-02","conditions":"Lymphoma","enrollment":700},{"nctId":"NCT03505762","phase":"PHASE2","title":"Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2018-07-19","conditions":"B-Cell Non-Hodgkin Lymphoma","enrollment":80},{"nctId":"NCT03054896","phase":"PHASE2","title":"A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-03-08","conditions":"Richter Syndrome","enrollment":69},{"nctId":"NCT04546620","phase":"PHASE2","title":"Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital Southampton NHS Foundation Trust","startDate":"2021-10-19","conditions":"Diffuse Large B Cell Lymphoma","enrollment":453},{"nctId":"NCT06977711","phase":"PHASE1","title":"Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2025-06-20","conditions":"Diffuse Large B-cell Lymphoma","enrollment":10},{"nctId":"NCT07057765","phase":"","title":"Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2025-05-05","conditions":"DLBCL - Diffuse Large B Cell Lymphoma, Markers of Inflammation","enrollment":40},{"nctId":"NCT03742258","phase":"PHASE1","title":"Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2019-03-13","conditions":"Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","enrollment":12},{"nctId":"NCT01359592","phase":"PHASE2","title":"S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2011-09","conditions":"Lymphoma","enrollment":159},{"nctId":"NCT03995147","phase":"PHASE2","title":"Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2019-08-29","conditions":"B Cell Lymphoma, Lymphoma, Lymphoma, B-Cell","enrollment":51},{"nctId":"NCT06742502","phase":"PHASE2","title":"Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-12","conditions":"Primary Mediastinal Diffuse Large B-cell Lymphoma","enrollment":30},{"nctId":"NCT00945724","phase":"PHASE2","title":"Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis","status":"COMPLETED","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2009-09-27","conditions":"Large B-cell Diffuse Lymphoma of Testis","enrollment":54},{"nctId":"NCT01974440","phase":"PHASE3","title":"A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-01-31","conditions":"Lymphoma","enrollment":403},{"nctId":"NCT01829958","phase":"NA","title":"Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-04","conditions":"Non Hodgkin Lymphoma (NHL), Diffuse Large B-cell Lymphoma (DLBCL)","enrollment":201},{"nctId":"NCT05798156","phase":"PHASE2","title":"Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2023-03-20","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":125},{"nctId":"NCT02964858","phase":"NA","title":"Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma.","status":"RECRUITING","sponsor":"Tata Memorial Hospital","startDate":"2016-11","conditions":"NonHodgkin Lymphoma","enrollment":840},{"nctId":"NCT06760039","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-01-10","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":112},{"nctId":"NCT06901999","phase":"PHASE2","title":"Methotrexate or Thiotepa Combined With R-CHOP and Orelabrutinib in CNSL Patients","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-04","conditions":"CNS Lymphoma","enrollment":23},{"nctId":"NCT06251180","phase":"PHASE1","title":"Phase Ib Study of Rocbrutinib in Combination with R-CHOP in Patients with Newly Diagnosed B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Guangzhou Lupeng Pharmaceutical Company LTD.","startDate":"2024-04-10","conditions":"B-cell Non-Hodgkin Lymphoma","enrollment":112},{"nctId":"NCT06890585","phase":"PHASE2","title":"Zanubrutinib, Chidamide, and Rituximab Induction With or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Li Zhiming","startDate":"2025-06-01","conditions":"BTK Inhibitors, Histone Deacetylase Inhibitor, Double Express Diffuse Large B-cell Lymphoma","enrollment":128},{"nctId":"NCT06891157","phase":"PHASE2","title":"Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-08-20","conditions":"Chidamide, R-CHOP Chemotherapy, DLBCL - Diffuse Large B Cell Lymphoma","enrollment":148},{"nctId":"NCT05350930","phase":"","title":"Multidisciplinary Care Program to Secure MEdication Therapy for HematoLOgy Patients Receiving Injectable Anticancer Drugs","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2022-06-09","conditions":"Chemotherapy Effect, G-CHOP Chemotherapy, R-CHOP Chemotherapy","enrollment":38},{"nctId":"NCT01865110","phase":"PHASE3","title":"R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2013-11","conditions":"Mantle Cell Lymphoma","enrollment":623},{"nctId":"NCT06158399","phase":"PHASE2","title":"AZA Combined With RCHOP in P53-mutated DLBCL.","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2023-11-22","conditions":"DLBCL - Diffuse Large B Cell Lymphoma, TP53","enrollment":52},{"nctId":"NCT06779435","phase":"","title":"A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-01-01","conditions":"DLBCL","enrollment":400},{"nctId":"NCT04566887","phase":"PHASE2","title":"Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2021-03-01","conditions":"Mantle Cell Lymphoma","enrollment":105},{"nctId":"NCT04517435","phase":"PHASE1, PHASE2","title":"ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma","status":"TERMINATED","sponsor":"Deepa Jagadeesh","startDate":"2021-04-28","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":13},{"nctId":"NCT01855750","phase":"PHASE3","title":"A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-09-03","conditions":"Lymphoma","enrollment":838},{"nctId":"NCT05144009","phase":"PHASE2","title":"A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)","status":"TERMINATED","sponsor":"ADC Therapeutics S.A.","startDate":"2022-06-21","conditions":"Diffuse Large B-cell Lymphoma","enrollment":41},{"nctId":"NCT03263026","phase":"PHASE3","title":"Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2018-03-20","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":256},{"nctId":"NCT05578976","phase":"PHASE3","title":"A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2023-02-08","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":900},{"nctId":"NCT03467373","phase":"PHASE1","title":"A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-03-13","conditions":"B-Cell Lymphoma, Non-Hodgkin Lymphoma","enrollment":111},{"nctId":"NCT01478542","phase":"PHASE3","title":"OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients with CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine","status":"COMPLETED","sponsor":"Universität des Saarlandes","startDate":"2011-11","conditions":"CD20+ Aggressive B-Cell Lymphoma","enrollment":1152}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":320,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CHOP-R","genericName":"CHOP-R","companyName":"CTI BioPharma","companyId":"cti-biopharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CHOP-R is a chemotherapy regimen that combines rituximab with a modified version of the CHOP regimen, which includes cyclophosphamide, doxorubicin, vincristine, and prednisone. Used for Non-Hodgkin lymphoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}